A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY agreed to acquire 2seventy bio, Inc TSVT. Meanwhile, other pipeline and ...
Queerty on MSN18h
A once-a-year PrEP injection? The results of the first clinical trial look promisingPharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Clinical Trials Arena on MSN14h
MSD to push for approval of HIV combo after Phase III successMSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.
Clinical Trials Arena on MSN14h
ViiV to trial twice-yearly HIV antibody dosing after Phase IIb successThe company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback